



Clinical Phase II biotechnology company targeting cancer drug resistance

Danish public company listed on the Swedish stock exchange

Overcoming chemotherapy resistance

MVA Oncology Network meeting – DEC 08, 2020

Disclaimer



*This presentation, which should be understood to include these slides, their contents or any part of them, any oral presentation, any question or answer session and any written or oral materials discussed or distributed during a company presentation (the "**Presentation**"), has been prepared by Scandion Oncology A/S ("**Scandion Oncology**" or the "**Company**"), to be used solely for a company presentation. The information contained in the Presentation is provided solely for this purpose.*

*This Presentation does not constitute or form part of, and should not be construed as, any offer, invitation, solicitation or recommendation to purchase, sell or subscribe for any securities in any jurisdiction and the Presentation does not constitute, and should not be considered as, a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 and do not constitute an offer to acquire securities in the Company. The Presentation is intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete disclosure. The Company is currently preparing a prospectus which is expected to be approved by and registered with the Swedish Financial Supervisory Authority (the "**SFSA**") around 24 November 2020 (the "**Prospectus**") relating to a rights issue of shares of approximately SEK 236 million resolved upon by the Company's board of directors on 16 November (the "**rights issue**"). The Prospectus presents risks connected to an investment in the Company, and prospective investors in the rights issue are advised to read the Prospectus in its entirety before making a decision whether to invest in the Company. The expected approval from the SFSA of the Prospectus should not be understood as an endorsement of the securities offered. The Company has not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "**Securities Act**"), or under any of the relevant securities laws of any state or other jurisdiction of the United States of America.*

Certain information contained herein has been obtained from published sources prepared by other parties that the Company has deemed to be relevant and trustworthy. No representation or warranty, express or implied, is made by the Company as to the accuracy, completeness or verification of any information contained in this Presentation. The Company has not made any independent review of information based on public statistics or information from an independent third party regarding the market information that has been provided by such third party, the industry or general publications.

Statements in this Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors as they relate to events and depend on circumstances that will or may occur in the future, whether or not outside the control of the Company. No assurance is given that such forward-looking statements will prove to be correct. Prospective investors in the rights issue should not place undue reliance on forward-looking statements. They speak only as at the date of this Presentation and the Company undertakes no obligation to update these forward-looking statements. Past performance does not guarantee or predict future performance. Moreover, the Company does not undertake any obligation to review, update or confirm expectations or estimates or to release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this Presentation.

This Presentation as well as any other information provided by or on behalf of the Company in connection herewith shall be governed by Swedish law. The courts of Sweden, with the District Court of Stockholm as the first instance, shall have exclusive jurisdiction to settle any conflict or dispute arising out of or in connection with this Presentation or related matters.

Investment Highlights



Targeting cancer drug resistance

rapid peak sales can be reached given a combination therapy application

Scandion Oncology A/S is a clinical Phase II biotechnology company developing **first-in-class, oral, add-on drugs to revert resistance to existing anti-cancer therapies.**

Targeting USD 37bn chemotherapy market growing at 12% annually

Well-documented mechanisms of action

enabling the company to target a wide variety of cancer indications

Lead candidate, SCO-101, currently in clinical Phase II trial targeting metastatic chemotherapy resistant colorectal cancer. Data readout from part 1 in Q2 2021

A **dose-range finding study targeting metastatic pancreatic cancer** was initiated in October 2020

Management and Board of Directors

track record of successfully developing biotechnology companies

Proven track-record of preclinical research, clinical trials and deal activities paves the way for **future commercial success whilst reducing execution risk**



**90% of cancer deaths are related to
cancer drug resistance**

Developing first-in-class add-on drugs targeting cancer drug resistance



Anti-cancer therapies



SCO-101



Addressing cancer drug resistance to complement standard anti-cancer therapies

SCO-101 has the potential to quickly reach peak sales


- By adding SCO-101, the aim is to offer **an improved response rate and increased survival time for cancer patients with drug resistant tumors**
- The current pipeline targets approximately 60% of currently used chemotherapies
- Initially, the company is targeting colorectal-, pancreatic- and breast cancer

- **SCO-101 will be subscribed together with the most commonly used anti-cancer therapies**
- Potential to be used in combination with first line anti-cancer therapy
- The mechanisms of action are enabling the company to target a wide variety of cancer indications – potentially increasing the addressable market


SCO-101 can be added in early stage- and metastatic cancer





SCO-101 has the potential to stop the progression of drug resistant cancer cells that survive chemotherapy treatment



SCO-101 in combination with chemotherapy eradicates drug resistant cancer cells




 Drug resistant cancer cells
 Drug sensitive cancer cells

Note: Schematic illustration

Growing addressable market




Chemotherapy market expected to grow 12% annually during 2020-2024¹




Source: 1) Market Research Future, 2019. 2) SEER Cancer, 2020.

Estimated incidence rates US, 2020²



Pipeline targeting 60% of currently used chemotherapies




SCO-101: Ongoing Phase II trial – metastatic colorectal cancer



Primary efficacy end-point: Objective response rate

Part 1

Part 2




12-18

Patients with metastatic and FOLFIRI resistant colorectal cancer



25

Patients with metastatic and FOLFIRI resistant colorectal cancer¹



1) The last 6 patients from the run-in study are included here


SCO-101: Dose-range finding / Phase II trial – metastatic pancreatic cancer



End-points: Safety, PFS, OS and clinical benefit rate



Part 1

Part 2



12-18

Patients with metastatic pancreatic cancer (PDAC)
SCO-101 + nab-paclitaxel and gemcitabine




40 + 30 patients with metastatic PDAC
First line SCO-101 + nab-paclitaxel and gemcitabine¹

20 + 20 patients with metastatic PDAC
First line nab-paclitaxel and gemcitabine¹



1) Interim analyses after the first 40 + 20 patients, where it will be decided whether to include additional patients
















Strategy to develop innovative first-in-class drugs



Targeting partnerships and licensing agreements post clinical Phase II trials

Example of recent deals within the oncology field¹



Completed date	Licensee/Buyer	Licensor/Target	Deal type	Deal stage	Upfront/ milestone	Total deal value
2020-09-15	 BAYER	 SYSTEMS ONCOLOGY	Licensing Agreement ²	Preclinical	USD 25/345m	USD 370m
2020-09-12	 MSD	 SeattleGenetics	Licensing Agreement	Phase II	USD 600/2600m	USD 3,200m
2020-07-22	 EQRx	 G1 THERAPEUTICS	Licensing Agreement ²	Phase II	USD 20/290m	USD 310m
2020-07-14	 Roche Genentech <small>A Member of the Roche Group</small>	 blueprint MEDICINES	Licensing Agreement ²	Pre-reg.	USD 775/927m	USD 1,702m
2020-01-06	 Pharma Mar	 Jazz Pharmaceuticals	Licensing Agreement ²	Pre-reg.	USD 200/800m	USD 1,000m
2019-12-19	 MSD	 ARQULE [®]	Acquisition	Phase II	n/a	USD 2,700m
2019-12-08	 apollomics	 GlycoMimetics, Inc.	Licensing Agreement ²	Phase III	USD 9/180m	USD 189m
2020-04-28	 ORIC		IPO	Phase I	Current market cap USD +1000m ³	

Source: Global Data

1) Deal descriptions in appendix 2) Royalties to be received on future net sales. 3) As per close 2020-10-27 (capitaliq.com).

Investment Highlights



Targeting cancer drug resistance

rapid peak sales can be reached given a combination therapy application

Scandion Oncology A/S is a clinical Phase II biotechnology company developing **first-in-class, oral, add-on drugs to revert resistance to existing anti-cancer therapies.**

Targeting USD 37bn chemotherapy market growing at 12% annually

Well-documented mechanisms of action

enabling the company to target a wide variety of cancer indications

Lead candidate, SCO-101, currently in clinical Phase II trial targeting metastatic chemotherapy resistant colorectal cancer. Data readout from part 1 in Q2 2021

A **dose-range finding study targeting metastatic pancreatic cancer** was initiated in October 2020

Management and Board of Directors

track record of successfully developing biotechnology companies

Proven track-record of preclinical research, clinical trials and deal activities paves the way for **future commercial success whilst reducing execution risk**

Leadership – track record of successfully developing biotechnology companies



Bo Hansen

President and CEO

- Seasoned top executive and life science entrepreneur
- Previously CEO of Genevant Sciences, Global Head & GM Roche, former executive in Santaris Pharma (acq. by Roche, USD 450m)



Nils Brüner

CSO and Co-founder

- Medical oncologist with extensive experience in cellular and molecular biology
- Previous executive positions at WntResearch and Oncology Venture
- Holdings: 1,085,370 shares



Carit Andersen

CFO

- Former CFO of AstraZeneca A/S, Denmark
- +15 years of experience in finance and biotech
- Holdings: 56,269 shares



Nicklas Roest

CRO

- Broad experience in drug development spanning from preclinical to early and late stage projects
- Holdings: 26,138 shares



Jan Stenvang

CTO and Co-founder

- Broad experience in cancer resistance mechanisms and clinical work in several companies
- Holdings: 1,391,064 shares



Peter Vestlev

CMO

- Medical oncologist with experience from regulatory issues regarding cancer drugs
- Vast experience from leading clinical trials
- Holdings: 56,865 shares



Annie Rasmussen

CCO

- Extensive oncology clinical research & operational experience from Oncology Clinics & Research Units
- Co-founder of Topotarget A/S, Founder of HealthCreationDK and CancerGuidesDK
- Holdings: 3,500 shares



Peter Høngaard Andersen
Chairman

- Co-founder of Acadia Pharmaceuticals, Zealand Pharma, Prexton Therapeutics (acq. by Lundbeck, USD 1,100m)
- Glycom (acq. by Koninklijke DSM, USD 830m), Epitherapeutics (acq. by Gilead Sciences, USD 65m)
- Holdings: 39,465 shares



Carl Borrebaeck
Director

- Founder of Immunovia AB and Senzagen AB, BioInvent International AB, and Alligator BioScience AB
- Holdings : 112,165 shares



Jørgen Bardenfleth
Director

- Former CEO of Microsoft Denmark, Intel and Hewlett-Packard
- Chairman of Copenhagen Healthtech Cluster, Lyngsoe Systems A/S, Dubex A/S and Symbion A/S.
- Holdings: 458,924 shares



Thomas Feldthus
Director

- Co-founder and former CFO of Saniona AB, co-founder and former CFO of Symphogen A/S



Christian Vinding Thomsen
Director

- Specialized in law and legal issues within the pharmaceutical industry and the pharmaceutical industry in general



Bo Hansen
Director

- President and CEO of Scandion Oncology



Annie Rasmussen
Director

- Elected employee representative of Scandion Oncology



Thank you Scandion Oncology A/S (SCOL)

**Overcoming
chemotherapy
resistance**

Contacts & Information



Scandion Oncology A/S
Fruebjergvej 3, Symbion
2100 Copenhagen, Denmark / phone: + 45 38 10 20 17
www.scandiononcology.com
For Investor Relations requests: ir@scandiononcology.com

Overcoming
chemotherapy
resistance